All patients (n=76) | No LGE (n=37) | LGE (n=39) | p Value | |
---|---|---|---|---|
Age, years | 54±14.9 | 54±14.1 | 54.3±15.8 | 0.93 |
Males, % | 60 (78) | 31 (84) | 29 (74) | 0.31 |
History of hypertension, % | 25 (32) | 15 (41) | 10 (26) | 0.16 |
History of diabetes mellitus, % | 16 (21) | 9 (24) | 7 (18) | 0.49 |
History of dyslipidaemia, % | 20 (26) | 12 (32) | 8 (21) | 0.28 |
History of smoking, % | 31 (40) | 15 (40) | 16 (41) | 0.98 |
History of VF or sustained VT, % | 15 (20) | 4 (11) | 11 (28) | 0.08 |
Length of hospital stay | 25.5±22.4 | 20±8.5 | 30.6±29.4 | 0.03 |
Clinical variables | ||||
Systolic BP, mm Hg | 123.3±25.4 | 131.7±27.1 | 115.4±21.2 | 0.005 |
Diastolic BP, mm Hg | 83.3±23.3 | 87.0±25.3 | 74.1±19.6 | 0.017 |
Heart rate, bpm | 92.6±25.2 | 97.8±26.5 | 87.9±23.4 | 0.09 |
Sinus rhythm, % | 63 (83) | 30 (81) | 33 (85) | 0.68 |
Complete LBBB, % | 18 (24) | 10 (27) | 8 (21) | 0.41 |
NYHA functional class, % | ||||
I | 1 | 1 | 0 | 0.50 |
II | 21 | 12 | 9 | |
III | 36 | 17 | 19 | |
IV | 18 | 7 | 11 | |
Medication at baseline, % | ||||
β-blocker | 73 (96) | 36 (97) | 37 (95) | 0.58 |
ACEi or ARB | 65 (86) | 30 (81) | 35 (90) | 0.28 |
Aldosterone antagonist | 52 (69) | 27 (73) | 25 (66) | 0.5 |
Loop diuretic | 51 (67) | 24 (65) | 27 (69) | 0.68 |
Digoxin | 9 (12) | 6 (16) | 3 (8) | 0.25 |
Statin | 22 (29) | 10 (27) | 12 (32) | 0.66 |
Aspirin | 8 (11) | 5 (13) | 3 (8) | 0.40 |
Warfarin | 33 (43) | 17 (46) | 16 (41) | 0.66 |
Amiodarone | 14 (18) | 6 (16) | 8 (20) | 0.62 |
Device implantation, % | ||||
ICD/CRT-D | 26 (34) | 9 (24) | 17 (43) | 0.09 |
Laboratory examination | ||||
Haemoglobin, g/dL | 14.1±2.6 | 14.4±2.5 | 13.7±2.0 | 0.23 |
Creatinine, mg/dL | 1.0±0.3 | 1.0±0.29 | 1.0±0.31 | 0.92 |
Sodium, mmol/L | 139.6±3.2 | 140.1±3.1 | 139.2±3.2 | 0.20 |
BNP at hospitalisation, pg/mL | 773.2±661.8 | 740.2±780.2 | 734.3±536.5 | 0.97 |
BNP at stable state, pg/mL | 290±252.7 | 239.1±233.4 | 338.2±263.8 | 0.08 |
Hs-CRP at hospitalisation, mg/dL | 0.81±1.53 | 0.88±1.5 | 0.74±1.5 | 0.68 |
Hs-CRP at stable state, mg/dL | 0.59±0.88 | 0.61±0.9 | 0.56±0.8 | 0.80 |
Cardiovascular MR measurements (SD) | ||||
LVEDV, mL/m2 | 155.8±71.5 | 149.5±67.5 | 161.8±75.5 | 0.45 |
LVESV, mL/m2 | 124.5±68.4 | 122.0±64.0 | 126.8±73.2 | 0.75 |
LVSV, mL | 53.9±20.8 | 48.6±16.9 | 58.9±23.0 | 0.028 |
LVEF, % | 21.9±9.7 | 19.7±6.1 | 24±12.0 | 0.053 |
LV mass index, g/m2 | 102.7±34.3 | 103.0±31.7 | 102.7±37.9 | 0.97 |
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BP, blood pressure; CRT-D, cardiac resynchronisation therapy combined with a defibrillator; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; Hs-CRP, high-sensitivity C reactive protein; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SV, stroke volume; Values are mean±SD or n (%). VF, ventricular fibrillation; VT, ventricular tachycardia.